Hemorrhagic Stroke clinical trials
15 active trials name this condition. Describe your situation to see which ones you may be eligible for.
By location
- Minocycline in Stroke Study at Maimonides
- Promoting Recovery After STroke With Amantadine
- kTMP-Enhanced Motor Rehabilitation for Chronic Stroke Recovery (KULMINATE) Pilot
- Improving Visual Field Deficits With Noninvasive Brain Stimulation
- Utility of CC7 Transfer in Stroke Subtypes
- Personalized Transcranial Direct Current Stimulation in Stroke Recovery
- Evaluation of the Efficacy of STRATAFIX for Neurosurgical Cranial and Spine Procedures
- Diagnostic Performance Study of the EMVision Emu™ Brain Scanner in the Detection of Intracranial Hemorrhage in Suspected Stroke Patients
- Genetic and Environmental Risk Factors for Hemorrhagic Stroke
- Feasibility of a Remotely Delivered Step Count Intervention in Chronic Stroke
- Risk of Recurrent CeAD After Pregnancy
- Recovery Trajectory for Coma and Disorders of Consciousness
- Stroke Recovery Initiative - Registry for Stroke Research Studies
- Amplitude Modulation Frequency Comparison in Kilohertz Transcranial Magnetic Perturbation (kTMP) for Chronic Stroke
- Wireless Nerve Stimulation Device To Enhance Recovery After Stroke
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Hemorrhagic Stroke” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.